CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy: Some patients with CIDP and MN were young individuals <30 years, and patients with CIDP and MN generally responded better to immunotherapy than patients with anti-CNTN1 antibody-associated AN.